ConductScience.org, home

Comparison · NCT01926041-70cd5c00

Intervention (FIT2 Program) vs Usual Care: Number of Participants With Regression to Normoglycemia

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Intervention (FIT2 Program) vs Usual Care: Number of Participants With Regression to Normoglycemia. Trial comparisons, record NCT01926041-70cd5c00. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01926041-70cd5c00

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1540.1160.201wilson
Risk in group 20.08060.05520.116wilson
Risk difference, group 1 minus group 20.07350.02160.127newcombe hybrid score
Risk ratio, group 1 over group 21.911.23.04log
Odds ratio, group 1 over group 22.081.233.5log
Number needed to treat, for one more participant with the outcome on Intervention (FIT2 Program) than on Usual Care13.67.8846.3from the risk difference interval

Groups2

Group 2 names the comparator: usual care.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Intervention (FIT2 Program)A 16-week FIT2 program that combines smoking cessation therapy with individualized behavior coaching in diet and physical activity for PCWG restriction.43279OG000
Group 2Usual CareUsual care comprises interpretation of laboratory results and encouragement to quit smoking and initiate a therapeutic lifestyle change for T2D prevention at each visit.25310OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Regression to Normoglycemia
Description
Participants who regress to normoglycemia should met all the following conditions for more than six months and maintained such status until the study end: 1) plasma glucose \<5.6 mmol/L (100 mg/dL) in the fasting state; 2) plasma glucose \<7.8 mmol/L (140 mg/dL) two hours after a 75-g oral glucose load; or 3) HbA1c\<39 mmol/mol (5.7%), in the absence of antidiabetic drugs.
Time frame
Up to 5 years
Population
Intention-to-treat analysis.

Source ClinicalTrials.gov

Trial

Title
The Effectiveness of Smoking Cessation in Prediabetic Smokers
NCT number
NCT01926041
Phases
NA
Conditions
Diabetes Mellitus, Cigarette Smoking, Prediabetes
Interventions
Varenicline for tobacco smoking cessation, Individualized counseling about both smoking cessation and weight control techniques
Lead sponsor
National Taiwan University Hospital
Results first posted
2023-02-22

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01926041-70cd5c00